Abstracts tagged "hypertension"

Abstract Number: 397 • 2016 ACR/ARHP Annual Meeting
Comorbidities Associated with Pediatric Psoriatic Arthritis
Cynthia Manos¹, Rui Xiao², Alexis Ogdie³, Timothy Brandon⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In adults, psoriatic arthritis (PsA) is associated with an increased prevalence of obesity, hypertension, and diabetes. It is not yet known if pediatric patients…
Abstract Number: 412 • 2016 ACR/ARHP Annual Meeting
Oral Glucocorticoids and Rates of Incident Diabetes Mellitus and Hypertension in Children with Juvenile Idiopathic Arthritis and Attention-Deficit/Hyperactivity Disorder
Daniel B. Horton¹, Fenglong Xie², Lang Chen², Melissa Mannion³, Brian L. Strom^4,5, Jeffrey Curtis⁶ and Timothy Beukelman⁷, ¹Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Diabetes mellitus (DM) and hypertension (HTN) are well-known toxicities of glucocorticoids (GCs), but the risks of these complications are unclear in children with JIA.…
Abstract Number: 859 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes of Renal Artery Involvement in Takayasu Arteritis
Seokchan Hong¹, Oh Chan Kwon², Byeongzu Ghang³, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Long-term Outcomes of Renal Artery Involvement in Takayasu Arteritis Background/Purpose: Takayasu arteritis (TA) involving the renal artery can result in hypertension, renal dysfunction, and premature…
Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Rishi J. Desai¹, Daniel H. Solomon², Sebastian Schneeweiss³, Goodarz Danaei⁴, Katherine Liao⁵ and Seoyoung C. Kim⁶, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…
Abstract Number: 1498 • 2015 ACR/ARHP Annual Meeting
Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology
Edmond Ramly¹, Diane Lauver² and Christie M. Bartels³, ¹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ²University of Wisconsin-Madison School of Nursing, Madison, WI, ³Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI
Background/Purpose: Despite routine blood pressure (BP) measurement by clinic staff, we reported that rheumatologists discussed elevated BPs in <1/3 of visits leading to missed opportunities…
Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting
EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…
Abstract Number: 1539 • 2015 ACR/ARHP Annual Meeting
Control of Modifiable Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Compared to Traditional High-Risk Cardiovascular Disease Patients
Brian LaMoreaux¹, Alexa Meara² and Wael N. Jarjour³, ¹Rheumatology, The Ohio State University, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease affecting one percent of the population. The main cause of mortality among RA patients…
Abstract Number: 1874 • 2015 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension
Helen Jin¹, John T. Granton², John Thenganatt³, Jakov Moric³, Ambika Gupta¹, Amie T. Kron¹, Cathy Chau¹ and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Poorer health outcomes for persons with chronic diseases have been reported in association with lower socioeconomic status (SES). No such evaluation exists for patients…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
Abstract Number: 2079 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression
Maite Castro¹, Eduardo Ferreira Borba¹, Michelle Lopes¹, Sandra G. Pasoto², Eloisa Bonfá¹ and Luciana Seguro², ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hypertension and persistent proteinuria are risk factors for renal disease progression and are associated with high salt intake, poor adherence to medication and smoking.…
Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Jeewoong Choi¹, Na Lu², Yuqing Zhang³, Sharan K. Rai⁴, Gary C. Curhan⁵ and Hyon K. Choi², ¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³BUSM, Boston, MA, ⁴Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…
Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Sylvie Perreault¹, Javier Nuevo², Scott Baumgartner³ and Robert Morlock⁴, ¹University of Montreal, Montreal, QC, Canada, ²AstraZeneca, Madrid, Spain, Madrid, Spain, ³Ardea Biosciences, Inc., San Diego, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting
Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Jeffrey R. Curtis¹, Ara Dikranian², Alan Mendelsohn³, Koshika Soma⁴, Haiyun Fan³ and Chudy Nduaka³, ¹University of Alabama at Birmingham, Birmingham, AL, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…
Abstract Number: 1434 • 2014 ACR/ARHP Annual Meeting
The Longitudinal Association Between Inflammation and Blood Pressure in Rheumatoid Arthritis
Chih-Chin Liu¹, Daniel H. Solomon², Rishi Desai³, Seoyoung C. Kim⁴ and Katherine Liao⁵, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ⁴Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose Inflammation is hypothesized to have direct effects on arterial endothelial and vasomotor function, functions which regulate blood pressure (BP). While inflammation has been implicated…
Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Matthew R. Lammi¹, Lesley Ann Saketkoo², Stephen C. Mathai³, Robyn T. Domsic⁴, Christine M. Bojanowski⁵, Virginia D. Steen⁶, Daniel E. Furst⁷ and Pharos Investigators⁸, ¹Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Medicine, Johns Hopkins University, Baltimore, MD, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, ⁶Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁷University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁸Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].